Contact us
Please complete the form below and a member of the OZURDEX® team will get back to you. Please fill in your details below if you are a registered healthcare professional and would like to request a meeting with an AbbVie representative.
OZURDEX® (dexamethasone intravitreal implant) is indicated for the treatment of adult patients with:
- Visual impairment due to diabetic macular edema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
- Macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
- Inflammation of the posterior segment of the eye presenting as non-infectious uveitis
Adverse events should be reported. Reporting forms and information can be found at XXXX
Adverse events should also be reported to AbbVie on GVPV@abbvie.com
Our therapy areas
Additional info
Report Adverse Event (AE reporting requirements to be localized)
This website is for Healthcare Professionals only
Job Number ALL-OZU-220048. Date of Preparation March 2023. This website has been developed and funded by AbbVie Ltd.
© 2019 AbbVie Ltd. All rights reserved. Registered number: 08004972 England.